Loading...
BCL-2 inhibition – stemming the tide of myeloid malignancies
Leukemia stem cells (LSC) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. (Lagadinou et al., 2013) and (Goff et al., 2013) find that LSC can be selectively targeted by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3705714/ https://ncbi.nlm.nih.gov/pubmed/23472867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2013.02.006 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|